Alfacell (ACEL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL)

ACEL 11.70

+1.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gil Kempenich who wrote ()	4/4/2000 9:13:00 PM
From: Gil Kempenich	Read Replies (1) of 1533

ASCO Meeting in May - FYI - I found the following reference: Oral Presentations - Phase III Randomized Trial of Onconase (ONC) vs. Doxorubicin (DOX) in Patients (Pts) with Unresectable Malignant Mesothelioma (UMM): Analysis of Survival. - N Vogelzang, R Taub, D Shin, J Costanzi, H Pass, J Gutheil, M Georgiadis, P McAndrew, K Kelly, H Chun, A Mittelman, S McCachren, K Shogen, S Mikulski, Univ of Chicago, Chicago, IL; Columbia Univ, New York, NY; M D Anderson Cancer Ctr, Houston, TX; Lone Star Oncology, Austin, TX; Wayne State Univ, Detroit, MI; Sidney Kimmel Cancer Ctr, San Diego, CA; Allegheny Cancer Ctr, Pittsburgh, PA; Cedar Sinai Medical Ctr, Los Angeles, CA; Univ of Colorado, Denver, CO; New York Medical Coll, Valhalla, NY; Thompson Cancer Survival Ctr, Knoxsville, TN; Alfacell Corp, Bloomfield, NJ. Monday 5/22/00, 3:45 PM - 4:00 PM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next